Pharmaceutical-mediated inactivation of p53 sensitizes U87MG glioma cells to BCNU and temozolomide

International Journal of Cancer

Volumn 116, Issue 2, 2005, Pages 187-192

  Xu, G Wei ^a,b   Mymryk, Joe S ^a,b   Cairncross, J Gregory ^c,d  

^a UNIVERSITY OF WESTERN ONTARIO   (Canada)

^b LONDON REGIONAL CANCER PROGRAM   (Canada)

^c UNIVERSITY OF CALGARY   (Canada)

^d FOOTHILLS HOSPITAL   (Canada)

Author keywords

BCNU; Cell cycle; Chemotherapy; DNA repair; Glioma; p53; Pifithrin ; TMZ

Indexed keywords

CARMUSTINE; CYCLIN DEPENDENT KINASE INHIBITOR 1; CYTOTOXIC AGENT; PIFITHRIN ALPHA; PROTEIN INHIBITOR; PROTEIN P53; SMALL MOLECULE PROTEIN INHIBITOR; TEMOZOLOMIDE; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CELL CYCLE; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CELL CYCLE S PHASE; CELL PROTECTION; CELL STRAIN U87MG; CHEMOSENSITIVITY; CONTROLLED STUDY; DNA DAMAGE; DNA REPAIR; DRUG MECHANISM; DRUG SENSITIVITY; GAMMA RADIATION; GENE INACTIVATION; GENE SILENCING; GLIOMA CELL; HUMAN; HUMAN CELL; ONCOGENE; PRIORITY JOURNAL; RADIATION PROTECTION; SENSITIZATION;

ANTINEOPLASTIC AGENTS, ALKYLATING; BENZOTHIAZOLES; BRAIN NEOPLASMS; CARMUSTINE; DACARBAZINE; DNA DAMAGE; DRUG INTERACTIONS; GLIOMA; HUMANS; THIAZOLES; TOLUENE; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P53;

EID: 22044437521     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/ijc.21071     Document Type: Article

References (32)

1. Oren M. Regulation of the p53 tumor suppressor protein. J Biol Chem 1999;274:36031-4.
2. Levine AJ. p53, the cellular gatekeeper for growth and division. Cell 1997;88:323-31.
3. Oren M. Decision making by p53: life, death and cancer. Cell Death Differ 2003;10:431-42.
4. El Deiry WS. The role of p53 in chemosensitivity and radiosensitivity. Oncogene 2003;22:7486-95.
5. Ferber D. Cancer research. A new way to combat therapy side effects. Science 1999;285:1651-3.
6. Komarov PG, Komarova EA, Kondratov RV, Christov-Tsetkov K, Coon JS, Chernov MV, Gudkov AV. A chemical inhibitor of p53 that protects mice from the side effects of cancer therapy. Science 1999;285:1733-7.
7. Komarova EA, Kondratov RV, Wang K, Christov K, Golovkina TV, Goldblum JR, Gudkov AV. Dual effect of p53 on radiation sensitivity in vivo: p53 promotes hematopoietic injury, but protects from gastrointestinal syndrome in mice. Oncogene 2004;23:3265-71.
8. Liu X, Chua CC, Gao J, Chen Z, Landy CL, Hamdy R, Chua BH. Pifithrin-alpha protects against doxorubicin-induced apoptosis and acute cardiotoxicity in mice. Am J Physiol Heart Circ Physiol 2004;286:H933-9.
9. Lorenzo E, Ruiz-Ruiz C, Quesada AJ, Hernandez G, Rodriguez A, Lopez-Rivas A, Redondo JM. Doxorubicin induces apoptosis and CD95 gene expression in human primary endothelial cells through a p53-dependent mechanism. J Biol Chem 2002;277:10883-92.
10. Culmsee C, Zhu X, Yu QS, Chan SL, Camandola S, Guo Z, Greig NH, Mattson MP. Reciprocal inhibition of p53 and nuclear factor-kappaB transcriptional activities determines cell survival or death in neurons. J Neurosci 2003;23:8586-95.
11. Zhang M, Liu W, Ding D, Salvi R. Pifithrin-alpha suppresses p53 and protects cochlear and vestibular hair cells from cisplatin-induced apoptosis. Neuroscience 2003;120:191-205.
12. Weller M. Predicting response to cancer chemotherapy: the role of p53. Cell Tissue Res 1998;292:435-45.
13. Xu GW, Nutt CL, Zlatescu MC, Keeney M, Chin-Yee I, Cairncross JG. Inactivation of p53 sensitizes U87MG glioma cells to 1, 3-bis(2-chloroethyl)-1- nitrosourea. Cancer Res 2001;61:4155-9.
14. Hirose Y, Berger MS, Pieper RO. p53 effects both the duration of G2/M arrest and the fate of temozolomide-treated human glioblastoma cells. Cancer Res 2001;61:1957-63.
15. Mantovani F, Banks L. The interaction between p53 and papillomaviruses. Semin Cancer Biol 1999;9:387-95.
16. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005;352:987-996.
17. Hara S, Nakashima S, Kiyono T, Sawada M, Yoshimura S, Iwama T, Banno Y, Shinoda J, Sakai N. p53-independent ceramide formation in human glioma cells during gamma-radiation-induced apoptosis. Cell Death Differ 2004;11:853-61.
18. Van Meir EG Kikuchi T, Tada M, Li H, Diserens AC, Wojcik BE, Huang HJ, Friedmann T, de Tribolet N, Cavenee WK. Analysis of the p53 gene and its expression in human glioblastoma cells. Cancer Res 1994;54:649-52.
19. Albertoni M, Daub DM, Arden KC, Viars CS, Powell C, Van Meir EG. Genetic instability leads to loss of both p53 alleles in a human glioblastoma. Oncogene 1998;16:321-6.
20. Vindelov LL, Christensen IJ, Nissen NI. A detergent-trypsin method for the preparation of nuclei for flow cytometric DNA analysis. Cytometry 1983;3:323-7.
21. Smith ML, Kontny HU, Zhan Q, Sreenath A, O'Connor PM, Fornace AJ Jr. Antisense GADD45 expression results in decreased DNA repair and sensitizes cells to u.v.-irradiation or cisplatin. Oncogene 1996;13:2255-63.
22. Ruan S, Okcu MF, Ren JP, Chiao P, Andreeff M, Levin V, Zhang W. Overexpressed WAF1/Cip1 renders glioblastoma cells resistant to chemotherapy agents 1, 3-bis(2-chloroethyl)-1-nitrosourea and cisplatin. Cancer Res 1998;58:1538-43.
23. Srivenugopal KS, Ali-Osman F. Stimulation and inhibition of 1, 3-bis(2-chloroethyl)-1-nitrosourea-induced strand breaks and interstrand cross-linking in Col El plasmid deoxyribonucleic acid by polyamines and inorganic cations. Biochem Pharmacol 1990;40:473-9.
24. Gupia N, Lamborn K, Deen DF. A statistical approach for analyzing clonogenic survival data. Radiat Res 1996;145:636-40.
25. Adimoolam S, Ford JM. p53 and regulation of DNA damage recognition during nucleotide excision repair. DNA Repair 2003;2:947-54.
26. McDonald ER III, Wu GS, Waldman T, El Deiry WS. Repair Defect in p21 WAF1/CIP1 -/- human cancer cells. Cancer Res 1996;56:2250-5.
27. Sheikh MS, Chen YQ, Smith ML, Fornace AJ Jr. Role of p21Waf1/Cip1/Sdi1 in cell death and DNA repair as studied using a tetracycline-inducible system in p53-deficient cells. Oncogene 1997;14:1875-82.
28. Xu GW, Mymryk J, Cairncross JG. Inactivation of p53 sensitizes astrocytic glioma cells to BCNU and temozolomide, but not cilsplatin. J Neuro-oncology (in press).
29. Wang Y, Zhu S, Cloughesy TF, Liau LM, Mischel PS. p53 disruption profoundly alters the response of human glioblastoma cells to DNA topoisomerase 1 inhibition. Oncogene 2004;23:1283-90.
30. Linke SP, Clarkin KC, Wahl GM. p53 mediates permanent arrest over multiple cell cycles in response to gamma-irradiation. Cancer Res 1997;57:1171-9.
31. Vogelstein B, Lane D, Levine AJ. Surfing the p53 network. Nature 2000;408:307-10.
32. Albrechtsen N, Dornreiter I, Grosse F, Kim E, Wiesmuller L, Deppert W. Maintenance of genomic integrity by p53: complementary roles for activated and non-activated p53. Oncogene 1999;18:7706-17.